Based in Cambridge, Massachusetts, Cullinan Oncology is committed to creating novel solutions for cancer patients. They are developing a wide range of therapeutics, including small molecules, monoclonal antibodies, kinase inhibitors, and protein degraders. Their team has varied backgrounds with expertise in protein engineering, drug discovery, immunology, and oncology. Cullinan Oncology was founded in 2017 by K. Dane Wittrup and Patrick Baeuerle.

Cullinan Oncology

Senior Manager, GCP/GVP/GLP Quality

Sr. Manager/Associate Director, Regulatory Affairs

In latest turn to autoimmune therapies, Cullinan nabs $280M to join lupus space - Endpoints News

Relapsed/Refractory Acute Myeloid Leukemia Market Growing Rapidly, Estimates DelveInsight | Key Companies Active in the Domain - Pfizer, Merck, Novartis, Astellas, Amgen, Janssen, Kartos, Cullinan Oncology, Meryx - PR Newswire

Ex-Intarcia dealmaker lands $150M for new cancer drug startup Cullinan Oncology - The Business Journals

Taiho Pharma, Cullinan Oncology join forces on EGFR ...

Cullinan rebrands, halts lymphoma trial to reflect autoimmune refocus - Fierce Biotech

Cullinan Management’s Strategic Shift and Capital Raise - TipRanks

With $150m in its pocket, new cancer startup will turn to CROs to ‘execute faster’ - OutSourcing-Pharma.com

Our team was thrilled to partner with Life Science Cares Boston again this year for our Annual Holiday Gift Drive. We are happy to make an impact together to support families served by Children's Services of Roxbury, Inc. this holiday season.

Nadim Ahmed - MedCity News

Yesterday, Cullinan Therapeutics was honored to attend the Massachusetts Conference for Women for an inspiring day filled with thought-provoking discussions, meaningful connections, and a shared commitment to driving change. 

Our Cullinan We-GEM (Women Empowered for Growth, Equity, and Mission) Community convened the night before to get ready for the conference and start planning our slate of dynamic programming for next year. 

What a wonderful few days of inspiration and learning with the incredible women shaping the future in healthcare, business, and beyond. 

Thank you to all the organizers and speakers of #MassWomen for creating such a special event!

Cullinan Therapeutics (CGEM) Stock Price, News & Analysis - MarketBeat

Cullinan, after $25M deal, hands back bispecific to Harbour

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations - PR Newswire

Cullinan Oncology and Taiho Pharmaceutical Complete - GlobeNewswire


              Boundless Science, Bold Decisions: Reflecting on a Year of Progress 
            

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases - GlobeNewswire

Cullinan Oncology Significantly Increases Ownership Stake - GlobeNewswire

Cullinan sets sail toward US with novel bispecific from Harbour BioMed for $25M in cash - Fierce Biotech

‘We need to do better:’ A biotech CEO on standing apart from the crowd - PharmaVoice

Cullinan changes name, pivots to autoimmune disease - BioPharma Dive

Embracing an open-minded approach to oncology drug development - STAT

Guest Blog: Patient-Focused Drug Development Is the Right Way to Drive Impact - Massachusetts Biotechnology Council

Today at 2 p.m. ET, at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, Antoine (Tony) Sreih, MD, Vice President of Clinical Development, will discuss clinical results of CLN-978, our CD19xCD3 bispecific T cell engager, in B cell lymphoma as well as the application of T cell engagers in #autoimmunediseases. 
 
Tomorrow at 2 p.m. ET, Tony will join a panel discussion on optimizing patient treatment procedure for the best outcomes, including ideal dosing, timing of procedures, conditioning regimens, and more. 
 
Learn more: https://bit.ly/3CLNPTC 

Cullinan Therapeutics - Massachusetts Biotechnology Council

The lung cancer community urgently needs the #biotech industry to adopt innovative strategies that push the boundaries of scientific progress.

In a blog post with MassBio, Jeff Jones, MD, MBA, Chief Medical Officer, discusses the importance of leaning into a “clinician’s mindset” and embracing collaboration to deliver new standards of care for people living with lung cancer and their families.

Read the full article: https://bit.ly/40XgxuK

#LungCancerAwarenessMonth #LCAM 

Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors - PR Newswire

AstraZeneca pays $63 million upfront for a Phase 1 ADC targeting Claudin 18.2 - PPF Group

EGFR-Non Small Cell Lung Cancer Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | AstraZeneca, J&J Innovative Medicine, Hansoh Pharma, Cullinan Oncology, Taiho Pharma - The Globe and Mail

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results - GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire

CLN-081 Receives Breakthrough Therapy Designation for NSCLC - AJMC.com Managed Markets Network

Today at 1:50 p.m. ET, Nadim Ahmed, President and CEO, and Jeff Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference in New York, NY. A live webcast and recording will be available here: https://bit.ly/4bD5WHU

Both ORRs in the water: Cullinan ASCO data near, J&J’s bispecific Rybrevant approved in NSCLC subset - BioWorld Online

Cullinan Oncology Licenses U.S. Rights to the First - GlobeNewswire

Cullinan rebrands with $280M private offering, expands beyond cancer - The Business Journals

Guest Blog: Biotech’s Role in Fostering Diverse, Equitable, and Inclusive Health Care - Massachusetts Biotechnology Council

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement - GlobeNewswire

Cullinan Oncology's CLN-619 shows promise for solid tumors - Drug Discovery & Development

Taiho Pharma, Cullinan Oncology join forces on EGFR drug for lung cancer - Fierce Biotech

Top ten oncology partnerships - Nature.com

#ICYMI: In a recent article with Springer Nature, we explore our efforts to address the need for therapies providing durable remission in #autoimmune diseases.  
 
Read the full article to learn more about our research into the potential of T cell engagers targeting CD19 to go beyond symptom control: https://bit.ly/48DPw16 

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development - Seeking Alpha

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? - Yahoo Finance

Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement - BioSpace

One of the hallmarks of #cancer is the ability to avoid detection by the immune system. With a significant unmet need for novel therapies that can help overcome immune evasion mechanisms used by tumors, our team is investigating CLN-619, a monoclonal antibody that binds to the extracellular region of MICA/B proteins. 
 
Learn more about the mechanism of action for CLN-619: https://bit.ly/4ht1Y86

On Sunday, December 8 at #ASH24, we will present a Trials in Progress poster on our Phase 1 study of CLN-049, a novel FLT3 and CD3 bispecific antibody, for the treatment of acute myeloid leukemia in patients with measurable residual disease. 
 
Get more details here: https://bit.ly/3V3Mg9E 

Cullinan Oncology Completes $131.2 Million Series C Financing - Business Wire

Cullinan's T-cell engager CLN-978 cleared by FDA to begin clinical studies for B-cell NHL - BioWorld Online

Taiho Pharma and Cullinan Oncology link up on cancer drug development - The Pharma Letter

Cullinan hands back bispecific to Harbour BioMed a year after paying $25M for US rights - Fierce Biotech

Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer - GlobeNewswire

Cullinan Oncology and Taiho Reunite to Co-Develop NSCLC Drug - BioSpace

Cullinan rebrands, halts lymphoma trial in autoimmune ...

At Flagship Biosciences, our client's success is at the heart of everything we do. We’re thrilled to have supported Cullinan Therapeutics in a novel investigational anti-MICA/B antibody being evaluated across multiple indications in solid tumors and hematologic malignancies.

Using our advanced multiplex immunofluorescence (mIF) services alongside state-of-the-art image analysis, we provided the high-quality biomarker and translational data that Cullinan featured in their recent poster at SITC 2024.

👏 Congratulations to the teams at Cullinan Therapeutics for their dedication and innovation in driving progress in immuno-oncology. Check out the poster here: https://loom.ly/Y5pGHyQ

If you're looking for a partner to support your biomarker and translational research, let’s connect!

#ImmunoOncology #ImageAnalysis #mIF #PrecisionMedicine #Collaboration

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug - BioPharma Dive

Cullinan Oncology and Taiho Pharmaceutical Announce - GlobeNewswire

CGEM IPO News - Oncology biotech Cullinan Oncology files for a $100 million IPO - Renaissance Capital

Cullinan bags $150M to build broad slate of cancer assets

Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com

Cullinan Oncology

Business:

Drug notes:

About: